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Abstract.  The major surface macromolecules of the 
protozoan parasite Leishmania major,  gp63 (a metal- 
loprotease), and lipophosphoglycan (a polysaccharide), 
are glycosylphosphatidylinositol (GPI) anchored. We 
expressed a cytoplasmic glycosylphosphatidylinositol 
phospholipase C  (GPI-PLC) in L.  major in order to 
examine the topography of the protein-GPI and 
polysaccharide-GPI pathways.  In L. major cells ex- 
pressing GPI-PLC, cell-associated gp63 could not be 
detected in immunoblots. Pulse-chase analysis revealed 
that gp63 was secreted into the culture medium with a 
half-time of 5.5 h.  Secreted gp63 lacked anti-cross 
reacting determinant epitopes, and was not metaboli- 
cally labeled with [3H]ethanolamine, indicating that it 
never received a GPI anchor. Further, the quantity of 
putative protein-GPI intermediates decreased ,,ol0-fold. 
In striking contrast, lipophosphoglycan levels were un- 
altered. However, GPI-PLC cleaved polysaccharide- 
GPI intermediates (glycoinositol phospholipids) in 
vitro. Thus, reactions specific to the polysaccharide- 
GPI pathway are comparianentalized in vivo within 
the endoplasmic reticulum, thereby sequestering 
polysaccharide-GPI intermediates from GPI-PLC 
cleavage.  On the contrary, protein-GPI synthesis at 
least up to production of Man(lat)Man(lot4)GlcN- 
(lat)-myo-inositol-l-phospholipid is cytosolic. To our 
knowledge this represents the first use of a catabolic 
enzyme in vivo to elucidate the topography of biosyn- 
thetic pathways. 
GPI-PLC causes a protein-GPI-negative phenotype 
in L. major,  even when genes for GPI biosynthesis are 
functional. This phenotype is remarkably similar to 
that of some GPI mutants of mammalian cells: impli- 
cations for paroxysmal nocturnal hemoglobinuria and 
Thy-l-negative T-lymphoma are discussed. 
LYCOSYLPHOSPHATIDYLINOSITOL  (GP1) t  anchors 
attach a diverse group of macromolecules to mem- 
branes in eukaryotes (see 19, 22 for recent reviews). 
The plasma membrane of the protozoan parasite  Trypmw- 
soma  brucei is covered with about 107 molecules of the 
variant  surface  glycoprotein (VSG), a GPI-anchored mole- 
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precursor; LPG, lipophosphoglycan; Man, mannose; mfVSG, membrane- 
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cule. The VSG GPI consists of dimyristoylphosphatidylino- 
sitol  linked to a linear tetrasaccharide "core glycan: The 
core glycan contains a glucosaminyl (GleN) and three man- 
nosyl (Man) residues with phosphoethanolamine (EtN-phos- 
pho)  at  the non-reducing  end,  EtN-phospho-6Man(la2)- 
Man(l~6)Man(lot4)GlcN.  The amino group of ethanolamine 
(EtN) is attached to the a-carboxyl of the COOH-terminal 
residue of the mature protein by an amide bond (23). 
Biosynthesis of GPIs in Z brucei begins with the transfer 
of N-acetylglucosamine (GIcNAc) from uridine 5'-diphos- 
pho N-acetylglucosamine  (UDP-GlcNAc) to phosphatidyl- 
inositol (PI),  forming GlcNAc-PI which is deacetylated to 
glucosaminyl-Pl (GIcN-PI). Sequential  transfer  of  mannosyl 
residues from dolichol-phosphoryl-mannose  (dol-P-man) 
yields Man3-GlcN-PI. Phosphocthanolamine is then added 
to Man3-GIcN-PI, producing glycolipid  ,~ (EtN-phospho- 
Man3-GlcN-PI). Replacement of the fatty  acids on glyco- 
lipid  A' with myristate  produces glycolipid  A  (also  termed 
P2 [39,  42])  which can be transferred  to nascent proteins  in 
the endoplasmic reticulum (consult 19, 22 for reviews). 
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no report on the topography of the GPI pathway in T. brucei. 
In this work we present evidence from the related trypanoso- 
matid LeishmanM major indicating that GPI biosynthesis is 
initiated on the cytoplasmic side of the endoplasmic reticulum. 
Leishmania major, a member of the family trypanosoma- 
tidae, is a causative agent of human leishmaniasis. L. major 
has copious amounts of GPIs termed glycoinositol phospho- 
lipids  (GIPLs)  which are  unattached to  macromolecules 
(45).  GPIs that are covalently bound either to polysaccha- 
rides  (lipophosphoglycan [LPG]  [46])  or proteins  (gp63, 
PSA-2,  gp46/M-2 [6, 20, 55, 59]) are also found in Leish- 
mania. The core glycan of the gp63 GPI anchor is identical 
to the core glycan of  the VSG GPI (62). The two GPI anchors 
differ in the kinds of  fatty acids and the nature of  their linkage 
to the glycerol of PI; instead of dimyristoyl glycerol, the L. 
major protein-GPI contains 1-O-alkyl-2-O-acyl  glycerol. A 
putative protein-GPI anchor precursor, LP-1, has been iden- 
tiffed in Leishmania mexicana (25).  Polysaccharide-GPIs of 
L. major contain a "phosphosaccharide core" consisting of 
a glucosaminyl, two mannosyl, and a galactofuranosyl resi- 
due,  Gal~l#3)Man(hx3)Man(lot4)GlcN,  attached to myo- 
inositol-l-phospho-lipid.  Hence, the Man(loM)GlcN(lc~6)- 
myo-inositol-l-phospho-lipid moiety is  found both  in  the 
core glycan of protein-GPIs and in the phosphosaecharide 
core of polysaccharide-GPIs. Consequently, it has been sug- 
gested that steps leading to the biosynthesis of Man(lo~4)- 
GlcN(lo06-myo-inositol-l-phospho-lipid  are  common  to 
both  polysaccharide and  protein-GPI  pathways.  Further, 
Man(la4)GlcN(hx)6-myo-inositol-l-phospho-lipid is inferred 
to be a branch point for the protein-GPI and polysaccharide- 
GPI pathways (43). Nevertheless, neither the site of synthesis 
of  Man(lot4)GleN(lcx)6-myo-inositol-l-phospho-lipid  nor 
the topography of the  subsequent PI-linked glycosylation 
reactions is known for either pathway. 
T.  brucei contains a  glycosylphosphatidylinositol phos- 
pholipase C (GPI-PLC) which can cleave dimyristoylglyc- 
erol from the VSG GPIarmhor (8,  12, 27, 31). The enzyme 
also cleaves protein-GPI precursors in vitro (39, 42).  GPI- 
PLC is an integral membrane protein (8, 27, 31, 50) that has 
been localized to the cytoplasmic side of intracellular vesi- 
cles (9).  We report the use of GPI-PLC to delineate the 
topography of  the two GPI pathways in L. major, and demon- 
strate compartmentalization of the protein and polysaccha- 
ride-GPI pathways. Our observations establish GPI-PLC as 
a valuable tool for studying the topography of GPI biosyn- 
thesis in vivo. To our knowledge this represents the first use 
of a catabolic enzyme in vivo to elucidate the topography of 
biosynthetic pathways. 
Intriguingly, L. major cells expressing GPI-PLC have the 
phenotype of protein-GPI deficient cells, although they have 
no defects in genes required for protein-GPI biosynthesis. 
This result has  implications on GPI-negative mammalian 
cells. Paroxysmal nocturnal hemoglobinuria (PNH) is a de- 
feet in affected hematopoietic stem cells resulting from a 
deficiency of GPI-anchored proteins (reviewed in 60). Lack 
of GleNAc-PI is a hallmark of affected cells (2, 32, 68). The 
GPI-negative phenotype of L.  major expressing GPI-PLC 
suggests that catabolism of GPI intermediates could explain 
the phenotype of some PNH and Thy-l-negative T-lymphoma 
mutants (29,  70). 
Materials and Methods 
Construction of  pX63NEO.GPI-PLC (pGPI-PLC) 
A  1.4-kb  EcoRI  fragment containing  T.  brucei  GPI-PLC  cDNA  was 
purified from pDH4 (30).  EcoRI overhangs were filled with Klenow, and 
the fragment was digested with HaeHI to remove a partial miniexon from 
the 5' end of the gene (61). The resultant Haelll-EcoRI fragment was blunt- 
end ligated  into BamHI  digested,  Klenow  treated,  pX63NEO  (40).  A 
recombinant, pX63NEO.GPI-PLC  (pGPI-PLC), with the GPI-PLC gene 
cloned in the same orientation as the dihydrofolate reductase-thymidylate 
synthase  transcriptional control region of pX63NEO  was selected. 
Culture of  Parasites, Transfection,  and Selection 
of  Recombinants 
Promastigote  (insect) stages of L. major strain LT252 CC-I clone (40) and 
the L.  major HOM/IQ/73/LCR-L32 strain (14) were studied.  Cells were 
maintained at 25°C in M199 medium supplemented with 10% FBS (Hy- 
clone Labs., Logan, UT) (complete medium). Parasites were transfected by 
electroporation and plating (36). LCR-L32 cells were selected in complete 
medium containing 50 #g/ml G418, and used without further cloning after 
adaptation to growth in 200 #g/mi G-418. 
Cell Lysis, Partial Fractionation,  and GPI-PLC Assay 
A pellet of l0  s cells was lysed in 1 ml hypotonic buffer (10 mM Tris-HCl 
pH 8, 2 mM EDTA) containing a protease inhibitor cocktail, consisting 
of phosphoramidon, ieupeptin, aprotinin, antipain, EDTA, and (4-amid- 
inophenyl)-methane sulfonyl  fluoride  (APMSF)  (Bochringer Mannheim 
Corp., Indianapolis,  IN).  The cell suspension was incubated on ice for 30 
rain, and centrifuged at 14,000 g for 15 min (4°C). The membranous pellet 
was extracted with 500/zl of 1X AB (50 mM Tris-HC1, pH 8, 5 mM EDTA, 
1% NP-40).  Protein solubilized in the detergent extraction was assayed for 
GPI-PLC  activity using [3H]myristate-labeled  VSG as  substrate (8,  27, 
31). Detergent extracts were diluted with 1X AB to obtain values within the 
linear range of the assay (0.1-1.5 U). 
Metabolic Labeling, Immunoprecipitation, 
and Kinetic Analysis 
Promastigotes  seeded at 106/ml and grown to a density of 107/ml (5 x  108 
total cells) were harvested by low speed centrifugation, washed in 10 ml 
of PBS (10 mM Na2HPO4, 2 mM KI-I2PO4, 137 mM NaC1, 8 mM KC1, 
pH 7.4), and washed twice in 10 ml of methionine-free  RPMI 1640 (GIBCO 
BRL,  Gaithersburg,  MD).  Parasites  were  resuspended  in  5  ml  of 
methionine-free RPMI (prewanned to room temperature) to which 500 t~l 
of FBS (dialyzed against methionine-free RPMI 1640) and 100/~1 of 1 M 
N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic  acid (Hepes), pH 7.4 had 
been added.  Parasites were labeled for 3 h with 250/~Ci of [35S]methio- 
nine (1,322 Ci/mmol, Amersham Corp., Arlington Heights, IL) (63). Cells 
were harvested, washed in 10 ml PBS, and placed in 7 ml of prewarmed 
complete medium supplemented with 100 ttg/ml non-radioactive methio- 
nine (17). A 1-ml aliquot of culture was withdrawn at 0, 1, 2, 4, 6, and 18 
h (unless otherwise stated), centrifuged  at 14,000 g for 5 min, and 980 #1 
of medium carefully  withdrawn into a prelabeled tube.  After removal of 
the remaining supernatant, pellet and media were both stored at -20°C 
until use. 
Parasites cultured in complete medium to a  density of  107/ml were 
washed as  described previously,  and resuspended  at a  density of 2  × 
107/Illl in 5  ml of ethanolamine labeling medium (M199  supplemented 
with 20 mM L-glutamine,  non-essential amino acids (Sigma Chem. Co., 
St. Louis, MO), 40 mM Hepes, pH 7.5, 20 mM NaOH, and 10% dialyzed 
FBS (Hyclone).  Cells were labeled overnight at 26°C with 100 #Ci/ml of 
[1-3H]ethanolamine hydrochloride  (50 Ci/mmol, American Radiolabeled 
Chemicals Inc., St. Louis, MO). Cells and media were harvested in 1-ml 
portions (see above). 
Glycoinositol  phospholipids (GIPLs) were labeled by incubating cells 
(4 x  107/ml) with [6-3H]galactose (40 Ci/rnmol, Amersham) at 50 #Ci/ml 
in glucose-free  RPMI (25)  supplemented with  10%  dialyzed  FBS (Hy- 
clone). Cells were labeled with [9,10-3H]myristate  (40 Ci/mmol, Amer- 
sham) al 100 ~Ci/ml (17) in serum-free M199 supplemented with 0.5 mg/ml 
of fatty acid free BSA (Sigma Chem. Co.) and 25 mM Hepes pH 7.4. Label- 
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scribed earlier. 
A pellet of 7  x  107 [35S]methionine-labeled cells was lysed by thorough 
resuspension in 1 ml of ice-cold immunopreeipitation dilution buffer (IDB) 
(1.25%  Triton X-100,  190 mM NaC1,  60 mM Tris-HC1,  pH 7.5,  6  mM 
EDTA,  10 U/ml Trasylol) (3), followed by incubation on ice for 30 min. 
A 250-/zl aliquot of cell lysate or culture supernatant, about 2  x  107 cell 
equivalents, was analyzed.  To the cell lysate 750 pl of 1.33x  1DB and 5 
al of anti-gp63 (or anti-cross reacting determinant, CRD) polyclonal anti- 
body was added (4). The solution was incubated at 40C overnight with con- 
tinuous mixing by inversion. A 100-tA portion of a 1:1 suspension of protein 
A-Sepharose beads (Sigma Chem. Co.) was added and the incubation con- 
tinued for 2 h at room temperature. Immune complexes adsorbed to protein 
A-Sepharose were washed three times, each for 10 rain, with 1 mi of immu- 
noprecipitation wash buffer (0.1% Triton X-100, 0.02% SDS, 150 mM Tris- 
HC1 pH 7.5, 5 mM EDTA,  I0 U/ml Trasylol). The beads received a final 
wash in lx TBS (3) after which 50 #1 of 2.5X Laemmli (SDS-PAGE sam- 
ple) buffer was added. Beads were vortexed briefly and heated at 90°C for 
5 rain. Protein in 25 ill of eluate was analyzed by SDS-PAGE (12%). The 
gel was soaked in Entensify  TM (Dupont), and radiolabeled proteins detected 
by fluorography with preflashed Hyperfilm-MP (Amersham).  14C-Labeled 
proteins (Sigma Chem. Co.) were used as molecular weight standards. For 
kinetic analysis  10/~1 of eluate was  qunntitated in a  liquid  scintillation 
counter (Beckman LS6000). 
Immunoblotting 
Promastigotes of Leishmania major LT252 CC-I clone adapted to growth 
in 32/~g/mi G418 were harvested at a density of 10711111. An aliquot of de- 
tergent extract (107 cell equivalents) prepared as described above was con- 
centrated (74), proteins were resolved by 12% SDS-PAGE and transferred 
to Immobilon-P membranes (Amicon, Bedford, MA). Cell-associated gp63 
was detected with anti-gp63 polyclonal antibody (14) and alkaline phospba- 
tase-conjugated secondary antibody (Boehringer Mannheim Corp.). Color 
development  was  achieved  with  5-bromo-4-chloro-3-indolylphosphate 
p-toluidine and nitro blue tetrazolium chloride (BioRad Labs.,  Hercules, 
CA). To detect lipophosphoglycan (LPG),  107 cell equivalents of total cell 
lysate was analyzed by Western blotting with monoelonal WIC 79.3 (38) 
(a gift from Dr. David Russell, Washington University). Color development 
was with alkaline phosphatase-conjugated secondary antibody. 
Immunofluorescence  Assays 
Cells  (105)  were  mounted  on  heavy  teflon-coated  slides  (Cell  Line, 
Newfield, NJ), air-dried for 1.5 h, and fixed with 2 % formaldehyde in PBS 
for 30 min at room temperature. Cells were washed three times in PBS, per- 
meabilized in 0.5% Triton X-100 for 30 rain at 4°C, and blocked with 10% 
FBS in PBS for 1 h at 25°C (37). After washing three times in PBS, a 1:10 
dilution  of polyclonal  antibody  directed  against the  20  amino-terminal 
residues  of GPI-PLC  polypeptide  was  added.  (In control  experiments, 
preimmune serum or antiserum against the Z brucei homologue of BiP [(5), 
a gift from Dr. Jay Bangs, University of Wisconsin], were used as primary 
antibodies.) Adsorption was allowed for 1 h, and cells were washed in PBS. 
Fluorescein isothioeyanate-conjugated anti-rabbit secondary antibody (1:500 
dilution) was then incubated with the cells for 1 h. Cells were washed with 
PBS, covered with 10% glycerol, and visualized by UV fluorescence mi- 
croscopy using a Zeiss inverted microscope (ICM 405). 
Isolation of Glycolipids and Thin 
Layer Chromatography 
A  washed pellet of 2  x  107 ceils that had been labeled separately with 
[3H]ethanolamine,  [3H]galactose,  or  [3H]myristate  was  extracted  twice 
with 500/zl of freshly mixed ice-cold chloroform/methanol (2:1,  vol/vol) 
(CM).  The partially delipidated cellular debris was then extracted twice 
with 500 ~1 of freshly mixed ice-cold chloroform/methanol/water (10:10:3) 
(CMW) (24). CM and CMW extracts were pooled separately, and dried un- 
der a stream of nitrogen gas. Dried extracts were partitioned in 500 tzl each 
of water and n-butanol. Pooled butanol phases were dried under a stream 
of nitrogen gas, and resuspended in 20 #1 of freshly mixed chloroform/meth- 
anol/water (10:10:3). Lipids were resolved by TLC on Silica gel 60 plates 
using CMW,  and detected  by  fluorography  with preflashed  Hypertilm  TM 
(Amersham). Quantitation of the fluorograph was performed on a Comput- 
ing Densitometer Model 300A (Molecular Dynamics,  Sunnyvale, CA). 
GPI-PLC Cleavage of GIPLs 
GIPLs extractx~ with CMW (see above) from [3H]galactose or [3H]myris- 
tate-labeled pX63NEO/L, major cells were dried and carefully resuspended 
in 1X AB by repeated pipeting (100/~1 per 2  x  107 cells, about 25  x  103 
CPM).  Recombinant GPI-PLC (200 ng) (50) was added and the mixture 
incubated at 370C for 3 h. Reaction was terminated by extracting twice with 
250/~l of water-saturated butanol. The butanol phases were pooled (about 
500/A) and back-extracted twice with 500/~l of water. Butanol phases from 
the  latter  extraction  were  dried  under  a  steam  of  nitrogen  gas  and 
resuspended in 20 t~l of freshly mixed CMW for TLC. 
Results 
GPI-PLC Decreases the Growth Rate of 
Leishmania major 
Cells transfected with either pX63NEO or pX63NEO.GPI- 
PLC (pGPI-PLC) grew well in medium containing 7 #g/ml 
G418. However, with increasing drug concentration, which 
is expected to raise copy number of the episomal expression 
vectors (and with it GPI-PLC levels), the growth rate of cells 
expressing GPI-PLC (pGPI-PLC/L. major  cells) decreased 
relative to cells harboring the vector pX63NEO (pX63NEO/ 
L. major  cells). At 32/~g/ml G418 the growth rate of pGPI- 
PLC/L. major is half that of control cells (Fig.  1 A). At a 
higher drug concentration (128/~g/rnl) pGPI-PLC/L, major 
cells which were seeded at  llY/mi appear to have growth 
arrested, one week after inoculation, at a density of 106/ml. 
Control  cells  reached  a  density  of  107/ml in  the  same 
period (Fig.  1 B). 
To  determine whether the  slow growth phenotype was 
directly related to GPI-PLC expression levels,  we quanti- 
tated GPI-PLC produced and compared it to the amount of 
enzyme found in T. brucei TREU 667 (51). No GPI-PLC- 
like  activity  was  detected  in  wild-type L.  major, or  in 
pX63NEO/L, major  cells (Table I). In pGPI-PLC/L, major 
clone//9 about the same quantity of GPI-PLC was produced 
as was found in Z  brucei (Table I); clone #4 produced 16- 
fold less GPI-PLC. However, both clones displayed the slow 
growth phenotype (Fig.  1,  and data not shown), and both 
clones appear to be devoid of cell-associated gp63  in the 
steady state (Fig. 2).  We conclude that we had expressed 
GPI-PLC in L. major  to the same level (or less) as present 
per cell in T. brucei, and that overexpression is not necessary 
for display of the slow  growth phenotype, or for cellular 
gp63 depletion (Fig. 2). 
GPI-PLC Is Associated with Cytoplasmic 
Membranous Structures 
The subcellular location of GPI-PLC in pGPI-PLC/L, major 
was investigated. In indirect immunofluorescence studies, 
specific staining occurred on cytoplasmic structures which 
emanated from the perinuclear region and frequently filled 
most of the cell. However,  the plasma membrane, kineto- 
plast, and nucleus were not stained. This staining pattern is 
reminiscent of the endoplasmic reticulum (ER) network. In 
control experiments, a  similar pattern of weaker intensity 
was observed when antibody against the  T. brucei homo- 
logue of BiP (5), an ER-resident protein, was used on these 
pGPIPLC/L, major  cells. Control pX63NEO/L, major  cells 
showed the ER-like staining pattern with anti-BiP antibody, 
but not with anti-GPI-PLC antibody. 
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Figure 1. Effect of GPI-PLC on growth of L. major. Ceils selected 
on M199 plates containing 7 #g/ml G418 were adapted to grow in 
different drug concentrations by step-wise increases in drug level. 
Growth rates were measured at the different G418 concentrations, 
by seeding cells at the indicated density and monitoring growth at 
stated intervals. 
Next, we determined whether GPI-PLC was soluble or as- 
sociated with particulate material. Cells were lysed in 1 ml 
ofhypotonic  buffer (Materials and Methods) and centrifuged 
for 15 rain at 14,000 g (4°C). Over 80% of the GPI-PLC ac- 
tivity present in the total lysate was associated with the pellet 
from this centrifugation (70/~1 vol), and could be extracted 
with IX AB (50 mM Tris-HC1, pH 8, 5 mM EDTA, 1% NP- 
Table L Levels of GPI-PLC in Cloned L. major CC-1 and 
T. brucei TREU  667 
GPI-PLC Activity 
Clone  Units (× 10-3)/109 cells 
pX63NEO/L,  major  Not detectable 
pGPI-PLC/L,  major clone 4  1.2 
pGPI-PLC/L,  major clone 9  20.0 
T.  brucei TREU 667  20.0 
A pellet of l0  s cells was lysed in  1 ml hypotonic buffer and centrifuged at 
14,000 g for 15 rain. The membranous pellet from the centrifugation was ex- 
tracted with IX AB and assayed for GPI-PLC. 
Figure 2. GPI-PLC expression in L. major  depletes cell-associated 
glX53. Ceils adapted to growth in 32/~g/ml G418 were harvested 
at a density of 107/ml, lysed hypotonically, and a detergent frac- 
tion prepared (Materials and Methods). An aliquot (107 cell equiv- 
alents) was concentrated by organic solvent precipitation (74), and 
proteins resolved by 12% SDS-PAGE. Cell-associated gi~53 was 
detected with anti-gp63 polyelonal antibody by immunoblotting. 
(Lane 1 ) pX63NEO/L, major; Oane 2) pGPI-PLC/L, major clone 
#4; (lane 3) pGPI-PLC/L, major clone #9. 
40). The remaining 20% of the enzyme activity might be as- 
sociated with lipid micelles that were not pelleted at 14,000 
g. Together with data from the immunofluorescence studies, 
these observations strongly suggest that GPI-PLC is asso- 
ciated with cytoplasmic membranous structures in L. major 
Lastly, we tested whether GPI-PLC entered the lumen of 
the ER.  The enzyme was immunoprecipitated from [3~S]- 
methionine-labeled cells and digested with N-glycarmse. A 
40-kD protein was specifically immunoprecipitated which 
was  insensitive  to  N-glycanase.  Thus,  the  four  potential 
N-glycosylation  sites of GPI-PLC are not available for glyco- 
sylation in the ER lumen. Controls with gp63 showed it to 
be N-glycosylated. These results suggest strongly that GPI- 
PLC does not enter the ER lumen. 
L. major Cells Expressing GPI-PLC Have Reduced 
Levels of  gp63 
The major  surface protein of L.  major is  a  63-kD  GPI- 
anchored glycoprotein, gp63 (20). We examined the trans- 
fected L. major cells for cell-associated gp63 as an indicator 
of the state of GPI metabolism. In Western blots using poly- 
clonal antibody against gp63 we detected very little gp63 in 
membrane fractions of pGPI-PLC/L, major clones (Fig. 2, 
lanes 2 and 3). The protein was detectable in control cells 
containing the vector, pX63NEO (Fig. 2, lane 1). We con- 
clude that  GPI-PLC  causes  a  decrease in  cell-associated 
gp63. 
Rapid Secretion of  gp63 Caused by GPI-PLC 
Several hypotheses, including the following, could explain 
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107/ml in complete medium were  labeled with  [35S]methionine 
and "chased" (Materials and Methods). Cell lysates or media (2 x 
107  cell  equivalents each)  were  immunoprecipitated  with  anti- 
gp63 polyclonal antibody. [3sS]Methionine-labeled  protein eluted 
from antibody-protein A complex was analyzed by SDS-PAGE  and 
fluorography. (A) L.  major LCR-L32:  (lane 1) total cell lysate 
(0 h chase), not immunoprecipitated; (lane 2) cells 0 h; (lane 3) 
medium 0 h; (lane 4) medium 1 h; (lane 5) medium 2 h; (lane 6) 
medium 4 h; (lane 7) medium 7 h; (lane 8) medium 16 h. (B) 
pGPI-PLC/L, major  LCR-L32: (lane 1 ) cells 0 h; (lane 2) medium 
0 h; (lane 3) medium 1 h; (lane 4) medium 2 h; (lane 5) medium 
4 h; (lane 6) medium 7 h; (lane 7) medium 16 h. Indicated time 
refers to hours of chase. 
the absence of gp63 in pGPI-PLC/L, major cells: (a) GPI- 
PLC inhibited synthesis of gp63;  (b) GPI-PLC caused re- 
lease  of gp63  from the plasma  membrane;  (c) GPI-PLC 
promoted gtgi3 secretion, or (d) GPI-PLC caused degrada- 
tion of gp63. We tested these hypotheses and distinguished 
between  them  by  metabolically  labeling  L.  major with 
[35S]methionine  followed by an examination of both cells 
and culture medium for gp63 (Fig. 3). Determination of the 
biochemical properties of released gp63 (product analysis) 
was particularly informative. 
L.  major wild-type  cells  were  efficiently labeled  with 
psS]methionine (Fig.  3 A, lane 1),  as were pGPI-PLC/L. 
major LCR-L32 cells (not shown).  In both cell types we 
could immunoprecipitate cell-associated gp63  after a  3-h 
pulse with psS]methionine (Fig. 3 A, lane 2; Fig. 3 B, lane 
/). In the ensuing "chase" glRi3 appeared in the medium of 
both cell types (Fig.  3 A, lanes 3-8;  Fig.  3 B, lanes 2-7), 
but with different kinetics. Compared to the total amount of 
gp63 present initially within cells, a  significant amount of 
gp63 was released in just 2 h of chase from pGPI-PLC/L. 
major cells: it took 7 h for a significant quantity of gp63 to 
accumulate in the medium of L. major wild-type cells. 
Immunoprecipitated gp63 was quantitated by liquid scin- 
tillation spectrometry of equal volumes of material eluted 
O.g 
i  0.6 
0.4 
i  0.2 
0.0 0  5  10  15  20 
TIME  of ehage,  h 
Figure 4.  Etfeet of GPI-PLC on the cell-association half-time of 
gp63. Gp63 was immunoprecipitated from cells or culture medium 
at specified times. A 10-#1 aliquot of material einted from the pro- 
tein A-Sepharose column (Fig. 3) was quantitated by liquid scintil- 
lation counting. Amount of labeled gp63 detected in the medium 
was normalized to the quantity of gp63 immunoprecipitated from 
cells at time zero (i.e., at initiation of chase, see Fig. 3) to obtain 
information presented on the y-axis. Data presented is a mean of 
duplicate determinations. A background of 50 CPM is subtracted. 
100% immunoprecipitated material corresponds to 795 CPM for 
L. major, and 528 CPM for pGPI-PLC/L, major cells. 
from the protein A-Sepharose column. For kinetic analyses, 
the quantity of gtgi3  present in the medium was expressed 
as a fraction of the amount of gp63 that was present within 
cells at the beginning of the chase (Fig. 4). Gp63 in L. major 
had an apparent half-time (time required for release of 50% 
of gp63 present at t =  0 h into medium) of at least 18 h (Fig. 
4).  Remarkably, in pGPI-PLC/L, major cells the apparent 
half-time of  gp63 cell-association decreased to 5.5 h (Fig. 4). 
Thus, for the latter cells which double every 24 h,  •94% 
of gp63 that was initially labeled is expected to be released 
within the generation time of each cell. The latter observa- 
tion is consistent with the apparent absence of gp63 from 
pGPI-PLC/L, major cells (Fig.  2) in steady-state analysis 
(Western blots). 
We conclude that pGPI-PLC/L, major cells appear to have 
no  cell-associated  gp63  because  the  bulk  of the  protein 
(~70%, Fig. 4) is secreted into the culture medium within 
7 h.  Electrophoresis of an aliquot of total culture medium 
followed  by  fluorography  revealed  three  other  proteins 
secreted into the medium with the same kinetics as gp63 
(data not shown). The identity of these proteins, which we 
presumed to be GPI-anchored, is unknown, however the ob- 
servation indicates that GPI-PLC effects are not limited to 
gp63. 
Gp63 Is Secreted Without Prior Addition of 
a GPI Anchor 
Release of a GPI-anchored protein into culture medium can 
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guish these possibilities, protein released from [35S]methio- 
nine-labeled L.  major cells was  immunoprecipitated with 
polyclonal antibody against either gp63 or against the cross- 
reacting determinant epitopes of cleaved GPIs (anti-CRD). 
Secreted gp63 was immunoprecipitable with anti-gp63 but 
not with anti-CRD (Fig. 5 A). The data suggests strongly that 
secreted glRi3 did not initially acquire a GPI anchor and then 
lose it by GPI-PLC cleavage, because when cleaved in vitro 
by PLC, gp63 reacts with anti-CRD (6,  62). 
We then tested  whether cells labeled  with  [3~S]methio- 
nine possessed anti-CRD epitopes. Total cell lysates were 
preincubated at 37°C for 1 h to allow endogenous phospholi- 
pases  C  to  cleave  [35S]methionine-labeled GPI  moieties, 
and then immunoprecipitated with anti-CRD antibody. As 
shown in Fig. 5 B, columns 1 and 2, cellular anti-CRD epi- 
topes can be immunoprecipitated, indicating that the anti- 
CRD  antibody  was  functional.  Consistent  with  the  extra 
phospholipase C activity in pGPI-PLC/L, major cells, due 
to expression of GPI-PLC, the quantity of immunoprecipita- 
ble anti-CRD antigens doubled (Fig. 5 B, column 2). 
The possibility remained that gp63 dissociated from the 
plasma membrane with its GPI anchor intact, in which case 
the released gp63 will not be detected by anti-CRD antibody. 
To  test  this  hypothesis,  released  [3sS]methionine-labeled 
gp63 was incubated with an excess of recombinant GPI-PLC 
(eGPI-PLC) to cleave the presumably intact GPI anchor. 
The anti-CRD epitopes should be exposed after this cleav- 
age, and the solubilized gp63 ought to be immunoprecipita- 
ble by anti-CRD antibody (a buffer containing 5 mM EDTA 
was used so as to protect GPI-PLC from the proteolytic ac- 
tivity of gp63). Data presented in Fig. 5 B, columns 3 and 
4, indicate that anti-CRD reactive epitopes are absent on the 
released gp63. The [3~S]methionine-labeled  gp63 could not 
be immunoprecipitated with anti-CRD  even after in vitro 
treatment with eGPI-PLC. We conclude that released gp63 
does not have an intact GPI anchor. 
Lastly, the cells were metabolically labeled with pH]eth- 
anolamine to test for the presence or absence of GPI core 
glycan components on released gp63. This was necessary be- 
cause gp63 could initially have received a GPI anchor that 
was subsequently cleaved by GPI-PLC. However, the anti- 
CRD epitopes could have been destroyed by the action of a 
phosphodiesterase present in the secretory pathway, or in the 
medium. Then, the results of the anti-CRD immunoprecipi- 
tations will be negative for entirely different reasons.  Se- 
Figure 5. Secreted gp63 never received a GPI anchor. (A) Secreted 
gp63 lacks anti-CRD Epitopes. Medium collected from [3~S]me- 
thionine-labeled pGPI-PLC/L,  major cells  was  immunoprecipi- 
tated  with polyclonal antibody against either  gp63 (lane  1)  or 
against the cross-reacting determinant (lane 2). Immune complexes 
were analyzed as described in Fig. 4 legend. (B) [35S]Methionine- 
labeled anti-CRD epitopes are immunoprecipitable from cell ly- 
sates. Cells were lysed (Materials and Methods), and then incubated 
at 37°C for 1 h to enhance cleavage of GPIs by endogenous phos- 
pholipases. Lysates were immunoprecipitated with anti-CRD anti- 
body. Material eluted from the protein-A Sepharose beads was 
quantitated by liquid scintillation spectrometry. A background of 
40 CPM is subtracted from the data presented. Media was adjusted 
to 1X AB, purified recombinant GPI-PLC (eGPI-PLC, 40 U) was 
added, and the mixture incubated at 37"C for 1 h. Anti-CRD epi- 
topes were assayed  as described above. Column 1, h  major; column 
2, pGPI-PLC/L, major; column 3 (height same as background), L. 
major medium plus eGPI-PLC; column 4 (height same as back- 
ground), pGPI-PLC/L, major medium plus eGPI-PLC. (C) Secreted 
gp63 cannot be metabolically labeled with l~H]ethanolamine. Cells 
(pGPIPLC/L.  major) were  labeled  with  [3H]ethanolamine, and 
media was harvested. Cells and media were immunoprecipitated 
with anti-gp63 antibody. Immunoprecipitated protein was eluted, 
resolved by SDS-PAGE, and detected by fluorography. (Lane 1) 
Immunoprecipitate from 2  x  107 cells; (lane 2) immunoprecipi- 
tate of spent culture medium (from 2  x  107 cells). 
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anolamine (Fig. 5 C, lane 2), but the residual cellular gp63 
(Fig. 4) could be labeled (Fig 5 C, lane 1 ). This result con- 
firms our earlier conclusion that  secreted gp63  never re- 
ceived a GPI anchor. Interestingly, similar analysis of gp63 
released by wild-type L. major indicated that it also never 
received a GPI anchor (not shown). Surprisingly, in Leish- 
mania amazonensis barely any gp63 is released from wild- 
type cells (not shown). Thus, in some Leishmania species 
(e.g., L. major) the requirement for GPIs might exceed the 
capacity of the biosynthetic pathway. 
Cleavage of the gp63 carboxyl terminal hydrophobic tail 
might not have occurred in pGPI-PLC/L, major, because we 
did not detect the expected increase in mobility of secreted 
gp63  on  SDS-PAGE  (compared to  cell-associated gp63). 
However,  we  have  not  ruled  out  the  possibility  that  the 
cleaved peptide was too small to produce a shift in the mobil- 
ity of secreted gp63. Lastly, we note reports that L. donovani 
chagasi and L. mexicana express gp63 transcripts that do not 
have GPI addition signals (47, 58, 73). If such proteins were 
present in L. major and were membrane bound, their cell as- 
sociation will not be expected to be affected by GPI-PLC. 
GPI-PLC Causes a Decrease of 
Protein-GPI Intermediates 
To test the hypothesis that GPI-PLC affected the biosynthesis 
of protein-GPI intermediates, glycolipids were isolated from 
[3H]ethanolamine-labeled cells  (107 equivalents)  and  ana- 
lyzed by TLC. A putative protein-GPI precursor, LP-1, is di- 
minished in pGPI-PLC/L, major ceils (Fig. 6 A, lane 2), as 
compared to pX63NEO/L,  major cells (Fig.  6 A, lane 1). 
Quantitation of LP-1 indicated that its level was reduced 10- 
fold in pGPI-PLC/L, major cells. LP-1 was confirmed as a 
GPI by cleavage with eGPI-PLC in vitro (not shown). A sec- 
ond putative GPI intermediate LP-2 (Fig. 6), less polar than 
LP-1,  was  decreased  about  sevenfold.  Amounts  of other 
[3H]ethanolamine-labeled lipids of higher relative mobility 
were  also  reduced.  However,  other  lipids  (marked  with 
asterisk) were present at similar levels in the two cell types. 
Some lipids (Fig. 6 A, marked with diamond) were slightly 
more abundant in pGPI-PLC/L, major cells as compared to 
the pX63NEO/L,  major cells. We conclude that GPI-PLC 
causes a decrease ofprotein-GPI anchor precursors in pGPI- 
PLC/L.  major cells.  The decrease in other ethanolamine- 
labeled lipids could be an indirect effect of LP-1 depletion 
(see Discussion), because those other lipids were not sensi- 
tive to eGPI-PLC cleavage. 
GP1-PLC Cleaves Polysaccharide-GPI 
Intermediates In Vitro, Yet Lipophosphoglycan Level 
Is Unaffected In Vivo 
The major surface macromolecule of L.  major is  LPG, a 
Figure 6. GPI-PLC decreases levels of  putative protein-GPI precur- 
sors. (A) Cells were labeled with pH]ethanolamine and extracted 
sequentially  with  chloroform/methanol  (CM)  and  chloroform/ 
methanol/water (CMW). CMW extract (107 cell equivalents) was 
analyzed by TLC (silica  gel  60)  in chloroform/methanol/water 
(10:10:3). Radioactive  species were detected by fluorography.  (lane 
/) pX63NEO/L, major; (lane 2) pGPI-PLC/L,  major  Migration 
positions of  pntative protein-GPI precursors, LP-1 and LP-2, are in- 
dicated.  Representative lipids that  are present  in roughly equal 
quantifies in each lane, per set of experiments, are indicated by an 
asterisk. Lipids that appear to be enhanced in pGPI-PLC/L, major 
cells are marked with failed  diamond. (B) LP-1 and LP-2 from Fig. 6 
A were quantitated by integrating  the volume under an elliptical  zone 
encompassing the respective fluorographic images using Image- 
Quant  TM ver3.0 software (Molecular Dynamics). The results of two 
separate experiments are presented. Sn'ppled column, pX63NEO/L. 
major; black column, pGPI-PLC/L, major. 
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cells expressing GPI-PLC, LPG levels did not decrease (Fig. 
7 A), in marked contrast to the results obtained with cellular 
gp63 (Fig. 2). This last result could be explained by a resis- 
tance  of  polysaccharide-GPI  intermediates  to  GPI-PLC 
cleavage,  or by sequestration of polysaccharide-GPI inter- 
mediates away from GPI-PLC in vivo. 
We therefore investigated the susceptibility of polysaccha- 
ride-GPI precursors (glycoinositol  phospholipids, GIPLs) to 
GPI-PLC, after their metabolic labeling with [3H]gaiactose 
(Fig. 7 B, lane 1 ). GPI-I, GPI-II, GPI-II], and GPI-IV (pre- 
sumably GIPL-I,  GIPL-2,  GIPL-3,  and lyso-GIPL-3, re- 
spectively (18),  see Fig. 8 for structures) were cleaved by 
eGPI-PLC in vitro (Fig. 7 B, lane 2). The least polar of the 
[3H]galactose-labeled  glycolipids GPI-X (possibly GlcNAc- 
PI formed after epimerization of galactose to glucose (26) 
was not cleaved (Fig. 7 B, lane 2), in accordance with the 
specificity of GPI-PLC  (50,  see  Fig.  8  legend).  Similar 
results  were  obtained  with  PH]myristate-labeled  GIPLs 
(not shown). We conclude that the in vivo effects of  GPI-PLC 
are specific to the protein-GPI pathway, despite the suscepti- 
bility of polysaccharide-GPI intermediates to GPI-PLC. 
Discussion 
GPI-PLC Causes Rapid Secretion of  GPI-Anchorless 
gp63: GPI Biosynthesis Is Initiated on the Cytoplasmic 
Side of the Endoplasmic Reticulum 
The GPI biosynthetic pathway has been studied extensively 
in many eukaryotes ranging from protozoan to mammalian 
cells. The topography of the pathway remains one of the in- 
triguing but unanswered questions in almost all of these 
cells. Do all the biosynthetic reactions take place in the ER 
cisternae where prefabricated GPI anchors are transferred to 
nascent protein? Or, does part of the pathway occur on the 
cytoplasmic leaflet of the ER? To address this issue in the 
trypanosomatid Leishmania major we employed a novel ap- 
proach based on the heterologous expression of a cytoplasmic 
membrane protein, GPI-PLC, which is capable of degrading 
GPI intermediates. Metabolism of a GPI-anchored protein, 
gp63,  was monitored vis-h-vis  GPI addition. Putative GPI 
anchor intermediates were quantitated. Results from these 
studies, in the context of the cytoplasmic localization of the 
catabolic enzyme, indicate that GPI synthesis is initiated on 
the cytoplasmic side of  the ER. The principles applied in this 
work could be extended to topological studies of  other mem- 
brane bound biosynthetic  pathways. For example, expression 
of a cytoplasmically  targeted/3-hexosaminidase or mannosi- 
dase could contribute to analysis of the topography of doli- 
chol-linked oligosaccharide biosynthesis. 
Figure 7. (A) Cellular lipophosphoglycan  is not decreased by GPI- 
PLC. Promastigotes adapted to growth in 32 /tg/ml (3418 were 
lysed by  suspension in  Laemmli buffer. An  aliquot (107 cell 
equivalents) was resolved by 12% SDS-PAGE, and probed with 
monoclonal WIC 79.3. (Lane 1) pX63NEO/L, major; (lane 2) 
pGPI-PLC/L, major  clone 4; (lane 3) pGPI-PLC/L, major  clone 
9.  (B) GPI-PLC cleaves polysaccharide-GPI intermediates. Gly- 
coinositol phospholipids obtained by chloroform/methanol/water 
extraction of [3H]galactose-labeled  pX63NEO/L, major (2  x  107 
cells) were dried and resuspended  in 100/~1  of IX AB. Recombinant 
GPI-PLC (200 ng) was either omitted (lane 1 ) or added (lane 2). 
The mixture was incubated at 37°C for 3 h. Butanol-extractable 
material was analyzed by TLC and fluorograpby. 
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Figure 8.  Topography of polysaccharide-GPI and protein-GPI pathways. It is proposed that reactions leading to the  synthesis of 
Man(lcx4)GlcN-PI  are membrane bound, and occur on the cytoplasmic  side of  the ER. In addition, the reactions are common to the protein- 
GPI and polysaccharide-GPI pathways  as previously suggested (43). A proportion of Man(lc~4)GIcN-PI flips into the ER lumen where 
it might be mannosylated by an cxl,3 transferase; it then enters the polysaccharide-GPI pathway. (The possibility that the complete 
polysaocharide-GPI  pathway  is lumenal can also be accommodated  by our data, consult text for details.) Man(loM)GlcN-PI  which remains 
on the cytoplasmic leaflet of the ER might be mannosylated  by a cytosolic cxl,6 transferase: the product of the latter reaction is committed 
to the protein-GPI pathway. Consistent with the shortage of LP-1 (Fig. 6 B), it is possible that the entire protein-GPI pathway occurs 
cytoplasmically.  Our data provides evidence for the first two mannosylations,  at least, of the protein-GPI pathway  occurring in the cytosol. 
*, denotes lipids that are not GPI-PLC substrates in vitro (Fig. 7 B, [8,  16, 27, 31, 50]). 
Intermediates of  GPI biosynthesis and GPI-anchored mac- 
romolecules are membrane bound (see  19,  22  for recent 
reviews). Localization of GPI-PLC to the cytoplasmic side 
of intracellular membranes (see below) and the enzyme's 
ability to cleave GPI biosynthetic intermediates in vitro (42, 
Fig. 7 B) suggested that GPI-PLC might cleave GPI inter- 
mediates in vivo if it were to colocalize with them. Such a 
situation could arise in any cell in which GPI-PLC is ex- 
pressed. L. major was particularly attractive for these stud- 
ies because: (a) The cells lack GPI-PLC-like activity (Table 
I);  (b)  intermediates  of  both  the  protein-GPI  and  the 
polysaccharide-GPI pathways can be cleaved by GPI-PLC in 
vitro (42, Fig. 7 B), and (c) topography of the two GPI path- 
ways is unknown; a comparative analysis had the potential 
of being very informative. 
Two models could explain the rapid release of gp63  in 
pGPI-PLC/L, major cells (Fig. 4).  The basic tenet of both 
models is that GPI-anchored proteins are committed to the 
secretory pathway by default, and are retained in the plasma 
membrane only by GPI addition (11, 13, 21, 67). In the first, 
the GPI-addition-cleavage model, gp63 was presumed to ini- 
tially acquire a GPI anchor in the ER. Subsequently, the pro- 
tein encountered GPI-PLC in transit to, or at, the plasma 
membrane, had the GPI anchor cleaved and was released. 
This model requires GPI-PLC to enter the secretory path- 
way. Further, since gp63 is presumed to receive a GPI an- 
chor before losing it, the model predicts that released gp63 
will have CRD epitopes. When cleaved by GPI-PLC, GPIs 
display  epitopes  on  GlcN(lu6)inositol  1,2  cyclic mono- 
phosphate which are recognizable by anti-CRD antibodies 
(7, 75). 
The second model is the GPI precursor depletion hypoth- 
esis. In this scenario, GPI-PLC is assumed to be associated 
with the cytoplasmic side of cellular membranes (including 
the ER). There, it encounters intermediates of GPI biosyn- 
thesis which it cleaves.  Degradation of GPI anchor inter- 
mediates creates a shortage of fully assembled GPI anchors 
in the ER lumen. Consequently, proteins with GPI addition 
signals (reviewed in 19) do not receive GPI anchors, and are 
secreted. Important distinctions between this model and the 
GPI-addition-cleavage model are (a) secreted proteins are 
predicted not to have anti-CRD epitopes, (b) residual com- 
ponents of the GPI core glycan [EtN-phospho-6Man(lc~2)- 
Man(lc~6)Man(lc~4)GlcN]  cannot be found on the secreted 
protein, and (c)  GPI-PLC is not required to enter the ER 
lumen. 
Our data supports the GPI precursor depletion model. 
First, GPI-PLC in L. major is membrane bound, cytoplas- 
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Therefore, any effects on GPI metabolism are exerted by 
GPI-PLC on the cytoplasmic side of cellular membranes. In 
addition, secreted gp63 never received a GPI anchor (Fig. 
5  A,  B,  and  C).  Moreover,  when  compared  to  control 
pX63NEO/L, major cells, pGPI-PLC/L, major cells have a 
tenth of the amount of a  putative protein-GPI precursor, 
LP-1,  presumably  EtN-phospho-Man3-GlcN-PI  (Fig.  6). 
Together,  these observations strongly support the concept 
that protein-GPI biosynthesis is initiated on the cytoplasmic 
leaflet of the ER. In agreement with this conclusion, over 
70 % of GlcN-PI (possibly the earliest glycolipid committed 
to the GPI biosynthetic pathway) is found on the outer leaflet 
of microsomes in the thymoma cell line BW5147.3 (72).  In 
addition, three genes cloned by complementation of GPI- 
deficient mammalian cells, Pig-A, GPI-H, and Pig-F, all ap- 
pear to encode cytoplasmic membrane proteins (33, 34, 52). 
GPI-PLC Does Not Inhibit the Polysaccharide-GPI 
Pathway: The First Two Mannosylation Reactions of 
the Protein-GPI Pathway Are Cytoplasmic 
LPG, a major surface macromolecule of L. major, is a GPI- 
anchored  polysaccharide.  LPG consists  of a  27-mer  (on 
the average)  of the disaccharide-phosphate backbone PO4- 
6Gal(l~4)Man(al), attached by a phosphosaccharide core, 
PO,-6Gal(lot6)Gal(1ot3)Gal~l/33)Man(1a3)Man(la4)GlcN, 
to a lyso-l-O-alkylphosphatidylinositol anchor (46,  71). L. 
major also contains copious quantities of  glycoinositol  phos- 
pholipids (GIPLs), GPIs that are not attached to protein or 
polysaccharide. GIPL-2, Gal(lt~3)Gal~l/33)Man(1ot3)Man- 
(lot4)GlcN-PI, is the most abundant of them. GIPL-3 con- 
tains a  1-O-alkyl-2-acyl  phosphatidylinositol linked to the 
identical  phosphosaccharide  core  found  on  LPG.  Lyso- 
GIPL-3 is presumed to be an intermediate in LPG biosyn- 
thesis (44). 
The polysaccharide-GPI and protein-GPI pathways appear 
to share several steps culminating in the production of Man- 
(I~4)GIcN-PI (Fig. 8) (43, 45). Thereafter, the protein-GPI 
pathway branches off from the polysaccharide-GPI pathway. 
The next mannosyl residue added to Man(lot4)GlcN-PI is in 
the od,3 configuration for polysaccharide-GPIs, but in the 
od,6 configuration for protein-GPIs. If inhibition of GPI me- 
tabolism in pGPI-PLC/L, major  occurred before Man(1ot4)- 
GlcN-PI production one would expect a  reduction in the 
amount of cellular LPG. Contrary to that prediction, LPG 
levels were not reduced (Fig. 7 A). Thus, the GPI-PLC inhib- 
itory effects (Figs. 2 and 6) are limited to the protein-GPI 
pathway. This specificity exists in spite of the susceptibility 
of polysaccharide-GPI intermediates to GPI-PLC in vitro 
(Fig. 7 B). 
To account for the in vivo specificity of GPI-PLC, we 
propose that the target of GPI-PLC occurs after Man(lo~4)- 
GlcN-PI synthesis. Thus, Man(1ot6)Man(1ct4)GlcN-PI,  or 
an intermediate occurring after it in the protein-GPI path- 
way, is the susceptible precursor.  Hence, the first manno- 
sylation specific to the protein-GPI pathway is cytoplasmic 
(Fig. 8). In contrast, the first mannosylation specific to the 
polysaccharide-GPI pathway,  which generates  Man(lo~3)- 
Man0t~4)GlcN-PI, occurs inside the ER, after ~flipping" of 
Man(la4)GlcN-PI  into  the  lumen.  Consequently,  Man- 
(loe3)Man(lo~4)GlcN-PI  is  sequestered  from  GPI-PLC, 
which remains on the cytoplasmic side of the ER. We sur- 
mise that reactions specific to the polysaccharide-GPI path- 
way are compartmentalized inside the ER, away from the 
protein-GPI pathway which is  chiefly cytosolic (Fig.  8). 
Man(lot4)GlcN-PI, the common intermediate, might not be 
cleaved in vivo for kinetic reasons:  it may flip rapidly into the 
ER lumen, or might be quickly mannosylated cytoplasmi- 
caUy to Man(la6)Man(lo~4)GlcN-PI, which is then cleaved. 
Alternatively, a pool of Man(lu4)GlcN-PI synthesized within 
the ER might be used for polysaccharide-GPI synthesis. How- 
ever,  we prefer the former model for reasons of "cellular 
economy." 
In effect, the topography of the GPI pathway is similar to 
that of dolichol-linked oligosaccharide biosynthesis. Both 
pathways are initiated on the cytoplasmic side of the ER (1, 
72),  yet the fully assembled precursors are transferred to 
protein inside the ER (1,  19,  22).  Intriguingly, dol-P-man 
might serve as a mannosyl donor in GPI synthesis on the cy- 
toplasmic side of the ER, but flips into the ER for use in the 
dolichol-linked oligosaccharide pathway (57). 
Z brucei GPI-PLC, an In Vivo Probe of the 
Topography of GPI Biosynthesis 
Several properties of T. brucei GPI-PLC suggested its poten- 
tial use as a  membrane-impermeable probe of the topog- 
raphy  of GPI  biosynthesis.  First,  the  enzyme is  highly 
specific for GPIs (10, 27, 31); it cleaves GPI anchors from 
proteins, and will cleave biosynthetic intermediates occur- 
ring after GIcNAc-PI if the inositol moiety is not acylated 
(16, 42, 49). Second, GPI-PLC is an integral membrane pro- 
tein even though Kyte-Doolittle analysis does not reveal  a 
"typical" transmembrane domain (8, 27, 31, 50).  GPI-PLC 
membrane insertion requires a 27-amino acid sequence from 
the carboxyl terminal half of the protein (Al-Qahtani, A., 
and K.  Mensa-Wilmot, unpublished observations).  Third, 
GPI-PLC does not enter the signal sequence-directed secre- 
tory pathway.  GPI-PLC entry into the secretory pathway 
would make product analysis uninterpretable, as the enzyme 
could encounter its substrate while both are in transit to the 
plasma membrane. 
In T. brucei, there is ample evidence indicating that GPI- 
PLC does not enter the secretory pathway: (a) GPI-PLC has 
been  localized by  immuno-electron microscopy of cryo- 
sections to the cytoplasmic side of intracellular membranes 
(9);  (b) GPI-PLC lacks a signal sequence needed to direct 
it into the lumen of the ER (12,  30);  (c)  GPI-PLC is not 
glycosylated, yet it has four potential N-linked glycosylation 
sites at positions 82, 101, 315, and 353 of  the 358-amino acid 
long protein (12, 30, 50); and, (d) GPI-PLC (by subcellular 
fractionation) is not found on the plasma membrane. It is as- 
sociated with intracellular organdies including nuclear and 
microsomal pellets (8, 28). Similarly, GPI-PLC in L. major 
is cytoplasmic, membrane bound, and unglycosylated. 
Conceptually, GPI-PLC could affect GPI synthesis in any 
cell in which it is expressed, if the cleavable GPI intermedi- 
ates (beginning with GlcN-PI) colocalized with it on the 
outer leaflet of the ER. In L. major, this prediction is borne 
out. GPI-PLC cleaves GPI intermediates, causing a protein- 
GPI negative phenotype (Figs. 2, 3, and 6). 
Interestingly,  the  GPI-negative  phenotype observed  in 
pGPI-PLC/L, major is not evident in bloodstream form T. 
brucei where GPI-PLC is endogenous. Each T. brucei cell 
has "~107 copies of a GPI-anchored VSG,  implying that a 
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ation  time  (,,o6-8  h)  of this  trypanosomatid.  The  cell- 
association half-time of VSG is about 34 h (9), unlike g1~53 
which has  a  cell-association half-time of 5.5  h  in pGPI- 
PLC/L. major cells. Why does GPI-PLC in T. brucei not 
cause a rapid release of  VSG, similar to the secretion of gp63 
in pGPI-PLC/L, major?. Previous  explanations relied on 
compartmentalization of GPI-PLC (which is cytoplasmic) 
from VSG (found at plasma membrane); those arguments 
might explain  why VSG  itself is  not cleaved.  However, 
recognizing now that protein-GPI anchor precursors can be 
cleaved by GPI-PLC in vivo, as demonstrated for the Leish- 
mania spp., an explanation other than compartmentalization 
is needed to rationalize why GPI precursors in T. brucei are 
not degraded. Our preliminary investigations indicate that 
GPI-PLC is posttranslationally modified in Z brucei  (Mensa- 
Wilmot, K., unpublished observations). We speculate that 
the modification (the nature of which is under investigation) 
regulates GPI-PLC action by keeping the enzyme activity 
quiescent, to prevent it from degrading GPI precursors un- 
der normal physiological conditions. An extracellular signal 
might trigger removal of the modification from the GPI- 
PLC, enabling it to become enzymaticaUy active. During 
hypotonlc lysis (a possible source of such an extracellular 
signal) almost all the VSG GPI is cleaved within 15 rain, pre- 
sumably by GPI-PLC (12). Possibly, the inhibitory effect of 
GPI-PLC on protein-GPI metabolism in pGPI-PLC/L, ma- 
jor occurs because GPI-PLC is constitutively active. Leish- 
mania species might not be capable of the posttranslational 
modification necessary to keep GPI-PLC quiescent. 
GPI-PLC Can Induce a GPI-Negative 
Phenotype: Implications  for Paroxysmal  Nocturnal 
Hemoglobinuria and Thy-l-negative T-lymphoma 
PNH is a  defect in a  hematopoietic stem cell progenitor, 
which after expansion usually manifests as hemolysis of the 
abnormal red cells. GPI-anchored complement regulatory 
proteins, e.g., C8 binding protein and CD55 (decay acceler- 
ating factor) (reviewed in 60), are markedly deficient in he- 
matopoietic cells from PNH patients. Increased plasma lev- 
els of CD55, suggestive of CD55 secretion, is also observed 
(15, 48, 56). GlcNAc-PI is deficient in lines of affected cells 
(2,  32,  68).  PNH cells are class A mutants in the T-lym- 
phoma nomenclature (2, 66) (see below). 
Several GPI-defective complementation groups of Thy-1- 
negative murine T-lymphoma cells have been established 
(reviewed in 69). The phenotype of the class E (defective in 
dol-P-man synthase [13]) and B (accumulates Man2-GlcN- 
PI  [35])  mutants bear  a  dramatic resemblance to pGPI- 
PLC/L. major cells.  Both class E  and B mutants secrete 
Thy-1 protein (21), similar to the secretion of gp63 by pGPI- 
PLC/L.  major. Further,  both  mutants  lack  EtN-phos- 
pho-Man3-GlcN-PI,  akin to  the  depletion of LP-1 (EtN- 
phospho-Man3-GlcN-PI)  in  pGPI-PLC/L,  major. Given 
that pGPI-PLC/L, major cells are not mutants in the GPI 
pathway,  our  observations  provide  evidence  that a  GPI- 
negative phenotype is inducible by catabolism of intermedi- 
ates. Thus, defects in genes whose products regulate the bal- 
ance between biosynthesis and breakdown of intermediates 
could produce a GPI-negative phenotype similar to that of 
pGPI-PLC/L, major. In support of this notion, treatment of 
the class B mutants with the aminoglycoside G418 can in- 
duce surface expression of Thy-1 protein, indicating that the 
class B defect is probably not in a gene of the GPI biosyn- 
thetic pathway (29). Instead, a hyperactive GPI mannosidase 
that degrades  Man3-GlcN-PI  may be  responsible  for the 
class  B  phenotype,  similar to  the postulated cleavage of 
Mane-GlcN-PI by GPI-PLC in pGPI-PLC/L, major. 
The ideas above can be extended to the class A, C, and 
H  mutants all of which,  similar to PNH cells, lack Glc- 
NAc-PI (64). One possibility for the existence of three com- 
plementation groups at the GlcNAc-PI synthesis step is a re- 
quirement for three different gene products for the GlcNAc 
transfer reaction (64). However,  most glycosyl transferases 
and hydrolases are single subunit enzymes (53, 65). There- 
fore, the GIcNAc transferase required for GPI biosynthesis 
might well be a single subunit enzyme. If so, some of the 
class A, C, or H mutations might be in factors that regulate 
GIcNAc-PI metabolism.  Some mutants might synthesize 
GlcNAc-PI which is then rapidly degraded by a hyperactive 
catabolic activity, e.g., a "Labile Regulator" of GPI biosyn- 
thesis (LR) (Fig. 9), similar to the degradation of protein- 
GPI precursors by GPI-PLC in pGPI-PLC/L, major. LR ac- 
tivity might be controlled normally by an "Inhibitor of the 
Labile Regulator" (ILR), possibly composed of at least two 
subunits (ILRA and ILRB, [Fig. 9]). Mutations in ILR might 
produce hyperactive LR leading to depletion of GIcNAc-PI, 
even when all genes for GPI biosynthesis are functional. The 
surprising finding that sodium butyrate causes reexpression 
of cell surface Thy-1 in class H mutants (29, 70) is compati- 
ble with this model; the compound might directly suppress 
LR  activity (or  stimulate ILR activity).  Interestingly, in 
agreement with  experimental  observations,  ILR mutants 
will not be dominant in cell fusion analysis. 
Consistent with this ILR hypothesis, the human Pig-A 
gene complements PNH and class A T-lymphoma cells, but 
fails to complement class C and H mutants (52).  Further, 
Pig-A has no sequence similarity with GIcNAc transferases, 
raising the possibility that Pig-A encodes an ILR. Mutations 
in Pig-A (as an ILR), as reported in PNH (68), might cause 
rapid degradation of GlcNAc-PI. However, the effect will be 
recessive, as observed in GlcNAc-PI biosynthesis studies in 
vitro (64). These observations suggest that kinetic analysis 
of GlcNAc-PI metabolism in PNH cells, and in some T-lym- 
phoma mutants, might be appropriate to rule out the possi- 
bility that absence of GIcNAc-PI in the steady state is the re- 
sult of very swift catabolism. 
Consequences of  the Protein-GPI-Negative  Phenotype 
in L. major 
GPI-anchored molecules serve many different functions in 
cells, as suggested by the diverse groups of macromolecules 
represented. Therefore, the consequences of a GPI-negative 
phenotype are expected to be diverse, and manifested differ- 
ently, in a cell type-specific fashion. In L. major  the protein- 
GPI-negative phenotype causes "slow growth" (Fig.  1),  at 
least. This slow growth might be due to a deficiency  in a GPI- 
anchored ectoprotein that serves as a growth factor receptor. 
Candidate molecules for such an ectoprotein include the L. 
major equivalents of the folic acid receptor, and a  cyclic- 
AMP-binding protein (41, 54).  Three other proteins were 
rapidly secreted,  in addition to gp63,  from pGPI-PLC/L. 
major cells; one of them might be the deficient molecule. 
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Figure 9.  On the control of GPI biosynthesis by a labile regulator 
(The labile regulator hypothesis). It is assumed, as observed in 
some GPI-negative murine T-lymphoma cells (70), that all genes 
for GPI biosynthesis are functional. We propose that GIcNAc-PI 
is subject to degradation by a factor, the "Labile Regulator" (LR), 
that is unstable during cell lysis. High activity of LR might prevent 
detection  of  GlcNAc-PI. LR activity might normally be suppressed 
by  an  inhibitor,  termed the "Inhibitor of the Labile Regulator" 
(1LR).  ILR might be composed of two gene products ILRA and 
ILRB (at least).  Mutations in ILRA and/or ILRB might permit 
hyperactivity of LR, which results in depletion of GIcNAc-PI. The 
possibility that the two layers of regulation are actually exerted on 
GlcNAc transferase itself, making the LR/ILR complex a regula- 
tory component of the enzyme, is compatible with this hypothesis. 
We propose that sodium butyrate (70) and (3418  (29) cause reex- 
pression of GPI-anchored proteins by either suppressing activity of 
LR directly, or by stimulating ILR activity. 
Other effects of this protein-GPI-negative phenotype on the 
biology of Leishmania  are under investigation. 
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